(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study

PURPOSE: (188)Re-HEDP is indicated for the treatment of pain in patients with painful osteoblastic bone metastases, including hormone-refractory prostate cancer patients. Efficacy may be improved by adding chemotherapy to the treatment regimen as a radiation sensitizer. The combination of (188)Re-HE...

Full description

Saved in:
Bibliographic Details
Main Authors: Lam, Marnix G. E. H., Bosma, Tjitske B., van Rijk, Peter P., Zonnenberg, Bernard A.
Format: Artigo
Language:Inglês
Published: Springer-Verlag 2009
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2724641/
https://ncbi.nlm.nih.gov/pubmed/19319526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-009-1119-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items